ArticleJournal of orthopaedic surgery and research2025
MiR-18b-3p promotes cell proliferation and metastasis by directly inhibiting PTEN expression in osteosarcoma.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS), the most prevalent primary malignant bone tumor in adolescents, demonstrates aggressive clinical behavior and poor prognosis. This study aimed to elucidate the functional role and molecular mechanism of miR-18b-3p in OS pathogenesis.
methodsThe miRNA microarray data from the GEO database were evaluated through GEO2R. The expression patterns of miR-18b-3p and PTEN were systematically analyzed using RT-qPCR and western blotting. A dual-luciferase reporter assay validated the direct targeting relationship between miR-18b-3p and PTEN 3'-UTR. Functional experiments included CCK-8, wound healing, and transwell invasion assays, and xenograft mouse models. Bioinformatics predictions were further supported by Gene Ontology enrichment analysis, protein-protein interaction network construction, and single-cell RNA sequencing analysis.
resultsIntegrated bioinformatics interrogation identified miR-18b-3p as a prognostically characteristic gene, with its overexpression strongly correlating with reduced overall survival in OS patients (p = 0.046). Clinical specimens and cellular models revealed marked upregulation of miR-18b-3p in OS tissues and cell lines (U2OS, MG63, HOS, SAOS2) compared to normal controls. PTEN was subsequently identified as a direct downstream target through complementary binding site verification, showing inverse correlation with miR-18b-3p expression. Functional experiments demonstrated that miR-18b-3p overexpression significantly enhanced malignant phenotypes, including cellular proliferation, migration, and invasion capacity, while PTEN restoration effectively reversed these oncogenic effects. Additionally, OS cells (HOS and SAOS2) secreted miR-18b-3p, and this paracrine mechanism potentially reprogrammed the tumor microenvironment through suppressing PTEN expressed in various immune and stromal cells.
conclusionsOur findings establish miR-18b-3p as a novel oncogenic regulator in OS pathogenesis through direct PTEN targeting, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.